Journal
ONCOIMMUNOLOGY
Volume 4, Issue 8, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1026534
Keywords
angiogenesis; B7 family; CD28 family; HHLA2; immunosuppression; immunotherapy; ligand; receptor; tumor microenvironment; TMIGD2
Categories
Funding
- NCATS NIH HHS [UL1 TR001073] Funding Source: Medline
- NCI NIH HHS [R01 CA175495] Funding Source: Medline
- NIDDK NIH HHS [R01 DK100525] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA175495] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK100525] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
